For Patients

You are here:
  1. Home
  2. For Patients

Understanding Multiple Myeloma

Multiple myeloma is a abnormal growth of a type of white blood cells called Plasma cells, which normally make antibodies. Multiple myeloma is characterized by the uncontrolled growth of these plasma cells. It is caused by distinct genetic mutations that differ between individuals.

Despite the introduction of numerous new therapies in the past decade, multiple myeloma remains one of the most challenging and hard to treat haematological malignancies with most patients requiring multiple lines of therapy.

PlasmaSEQ paves the way for a revolution in myeloma diagnostics with an assay that provides a more detailed analysis of myeloma than any previous tests allowing much better selection of therapies.

The PlasmaSEQ Process

While FISH tests have been the standard in myeloma for almost 2 decades now, they are extremely limiting in terms of resolution. FISH can in general only identify abnormalities that involve atleast 100,000 to 200,000 abnormal DNA molecules.

PlasmaSEQ however can do this as a resolution of 1 abnormal DNA molecule thus bringing a new paradigm to myeloma care.

In Multiple Myeloma (MM), NGS has been used to explore the genomic landscape and identify key genetic mutations. However, it has yet to be widely adopted in routine clinical practice worldwide.

Why Choose PlasmaSEQ

Feature

Eliminates the requirement for multiple assays such as FISH and karyotyping. It is also capable of detecting mutations, including TP53 and others, that are not identified by FISH.

Advantage

Minimal DNA input allowing testing from very little sample volume

Dramatically increased resolution of testing

Comprehensive genomic overview

Rapid results

Data Reviewed by experts in Myeloma